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Abstract
Background: Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional
treatment for patients with stage II-III esophageal cancer. However, there are some demerits in this regimen
because CDDP administration requires a large transfusion volume and 5-FU must be continuously infused over
24 h. Therefore, hospitalization is unavoidable. We collected retrospectively the data of definitive CRT with
nedaplatin and S-1 as carried out in our institution.
Methods: Patients with early and advanced esophageal cancer and relapsed esophageal cancer after radical
surgery were included. Nedaplatin 80 mg/m2 was given on days 1 and 29, and S-1 80 mg/m2 on days 1-14 and
29-42. No prophylactic treatment with granulocyte colony stimulating factor was administered. Patients received
two courses of concurrent radiotherapy of more than 50 Gy with or without two additional courses as adjuvant
therapy every 4 weeks.
Results: Between August 2011 and June 2015, 89 patients (age range, 44–86 years; K-PS 90–100, 81 %; squamous
cell carcinoma histology, 97 %; definitive/salvage CRT, 75/25 %) were collected. Twenty-one (24 %) patients
completed four cycles, and 94 % received two or more cycles. Grade 4 leukopenia, thrombocytopenia, and anemia
occurred in 12, 7, and 10 % of the patients, respectively. Five patients developed febrile neutropenia. Grade 3
non-hematological toxicity included infection in 12 %, mucositis/esophagitis in 3 %, kidney in 3 %, and fatigue in
3 %. Sixty-four patients (72 %) received the prescribed full dose and full cycles of chemotherapy. A complete
response was achieved in 76 patients (85 %). The 3-year overall survival rate was 54.4 % in definitive CRT and
39.8 % in salvage CRT, respectively. Sixty-two subjects (70 %) received treatment as outpatients.
Conclusions: Nedaplatin and S-1 in combination with radiotherapy is feasible, and toxicity is tolerable. This
treatment method has the potential to shorten hospitalization without impairing the efficacy of CRT.
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Introduction
Concurrent chemoradiotherapy (CRT) is well established
as a standard approach to treat esophageal cancer.
Cis-diammine-glycolatoplatinum (nedaplatin) is a plat-
inum derivative that was developed with the aim of re-
ducing renal toxicity while maintaining the effectiveness
of CDDP [1]. In an in vivo study, a combination of neda-
platin (NDP) and 5-FU has been shown to be as effective
as a combination of CDDP and 5-FU [2]. In a clinical
study, combination chemotherapy using NDP and 5-FU
has been reported to be a safe and effective method for
treating advanced esophageal cancer [3, 4].
S-1 (TS1 ®; Taiho Pharmaceutical Co. Ltd., Tokyo,
Japan), a new biochemical modulator of 5-FU, is an oral
dihydropyrimidine dehydrogenase (DPD) inhibitory fluor-
opyrimidine based on the biochemical modulation of 5-
FU [5–7]. The advantages of S-1 compared with 5-FU are
greater convenience because of its oral formulation and
continuous delivery, without intravenous infusion. S-1
is frequently used as a substitute for 5-FU in gastric
cancer, but limited data are available for esophageal
cancer [8]. Recently, combination chemotherapy with
S-1 and cisplatin has been widely studied in advanced
gastric cancer [9–11].
To our knowledge, there are no reports published on
definitive CRT with S-1 and NDP in patients with re-
sectable esophageal cancer. We designed this study as a
pilot study using concurrent CRT with NDP and S-1 in
early, advanced, and recurrent esophageal cancer. From
the tolerability and clinical efficacy of this regimen, we
evaluated retrospectively the possibility of introducing
this new chemotherapeutic regimen, with concurrent ra-
diation therapy, in the treatment of esophageal cancer.
Patients and methods
Chemotherapy regimen
All patients received chemotherapy concurrent with ir-
radiation. Chemotherapy consisted of two cycles of S-1
(80 mg/m2/day, days 1–14 and days 29–42, continu-
ously) combined with NDP (80 mg/m2, day 1 and day
29, bolus); standard techniques were used for hydration
and alkalization. For patients 75 years old or older, doses
were reduced to 80 % of both S-1 and NDP without ad-
juvant chemotherapy. Chemotherapy was started on the
first day of irradiation. After concurrent CRT, in the ad-
juvant setting one or two cycles of the same dose of
chemotherapy were added for patients who still had suf-
ficient bone-marrow function and performance status
and who did not refuse additional chemotherapy, al-
though old patients and patients with stage I disease
were excluded. When grade 4 myelosuppression was
seen and patients had recovered, doses were reduced to
80 % dose of both NDP and S-1 in the subsequent cycle
or later.
In consideration of concurrent radiation therapy, S-1
was used at a dose of 80 mg/m2/day on days 1 through
day 14, followed by a 2-week rest, and NDP was deliv-
ered intravenously at 80 mg/m2 on day 1 every 4 weeks.
After the CRT, the chemotherapy was repeated up to a
total of four cycles in order to maintain the response or
to extinguish the residual tumor (Fig. 1).
In our institution, NDP plus S1 have been adminis-
tered for all patients regardless of renal or cardiac func-
tion since August 2011. Standard regimen of CDDP plus
5-FU has never been performed over this time period.
Radiotherapy planning
All patients receiving definitive CRT were treated with
50.4 Gy delivered over 5.6 weeks at 1.8 Gy per fraction
or 50 Gy in 25 fractions over 5 weeks. No elective irradi-
ation on the mediastinal lymph nodes was performed.
Enhanced computed tomography (CT) and/or PET and
endoscopic extension were used to define gross tumor
volume (GTV) for each patient. All LNs with a diameter
at least 1 cm in short axis in CT or positive by 18FDG-
PET (excluding physiological accumulation) were in-
cluded in the GTV. The positive was defined as more
than 2.5 of standardized uptake value-max. Clinical tar-
get volume (CTV)-GTV margin was 2 cm in the cranio-
caudal direction and none in the other four directions
for the primary tumor. CTV was equal to GTV for
metastatic lymph node. We calculated the internal target
volume (ITV) which integrated the respiratory motions
of CTV in each patient using 4D-CT [12]. Planning tar-
get volume (PTV)-ITV margin was 0.5 cm in all six
directions.
All patients on salvage CRT received involved field ir-
radiation that covered only GTV plus margin and were
treated with 60 Gy delivered over 6 weeks at 2 Gy per
fraction. The CTV-GTV margin was 0.5 cm in all direc-
tions. The way how ITV and PTV were created was
same as the above for definitive CRT cases.
The details of radiotherapy planning and target vol-
ume definition of both definitive CRT and salvage CRT
were discussed in our previous reports [13–15]. 3D con-
formal radiation therapy was used to treat these patients.
Patients
The stage of esophageal cancer was classified according
to the UICC version 7 [16]. For staging, upper gastro-
intestinal endoscopy, X-ray fluoroscopic examination
with barium or gastrografin contrast, enhanced CT, and
fluoro-deoxy-glucose (FDG)-PET were performed before
definitive CRT or radical surgery.
We defined the indications for CRT using this regimen
as (a) lower and upper age limits of 20 years and 85 years,
respectively; (b) histopathologically proven squamous cell
carcinoma or adenocarcinoma of esophagus; (c) clinical
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stage I without indication for endoscopic sub-mucosal dis-
section or endoscopic mucosal resection, clinical stages
II–III, clinical stage IV consisting of metastases in the
supraclavicular/abdominal para-aortic lymph nodes in the
definitive CRT group and locoregional oligo recur-
rence of esophageal cancer after radical surgery in
the salvage CRT group; (d) Karnofsky-performance
status >70 %; (e) white blood cell counts of 4,000–
12,000/mm3, neutrophils >2,000/mm3, platelets >100,000/
mm3, hemoglobin >9.0 g/dL, total-bilirubin <1.5 mg/dL,
glutamate oxaloacetate transaminase/glutamate pyruvate
transaminase <76/72 U/L, serum creatinine value <1.2 mg/
dL (creatinine clearance values were not used as inclusion/
exclusion criteria), and partial pressure of arterial oxy-
gen >70 mmHg.
The exclusion criteria were: (a) presence of serious
complications including fresh gastrointestinal bleeding,
active infection, heart failure, renal insufficiency, liver
failure, or uncontrolled diabetes; (b) presence of active
overlapping cancer; (c) metastasis to other organs from
esophageal cancer; (d) a history of RT for the same le-
sion; (e) contra-indication to receive NDP/S-1; (f ) hyper-
sensitivity to NDP/S-1.
Follow-up method
Blood counts and laboratory tests were performed once a
week during CRT. Recurrence was monitored by measur-
ing the levels of the serum tumor markers carcino-
embryonic antigen (CEA), squamous cell carcinomarelated
antigen (SCC), cytokeratin 19 fragment (CYFRA), p53 anti-
body every month after completion of treatment and upper
gastrointestinal endoscopy (+/−biopsy) plus enhanced CT
scan from the upper neck lymph node to the bottom of
the pelvis scheduled every three months. When a recur-
rence was questionable by any of the above examinations,
FDG-PET was also performed. We are using Common
Terminology Criteria for Adverse Events version 4.0 to
measure toxicity.
Statistical analysis
The Kaplan–Meier method was used for estimation of
overall survival, loco-regional control, and disease-free sur-
vival. The times for survival were calculated from the start
of RT. 95 % CI was calculated by +/−1.96 × standard error.
Results
Demographics
The characteristics of the 89 patients (72 males and 17 fe-
males) are listed in Table 1. The median age was 65 years,
ranging from 44 years to 86 years. The tumor histology
was squamous cell carcinoma in 86 patients and adeno-
carcinoma in the other three patients. The sub-sites of the
primary tumors included cervical/upper/middle/lower
thoracic portions, with the following distribution: 6/17/
52/26 %, respectively. Clinical stage I comprised 21 %, II–
III 67 %, and IV 12 % in the definitive CRT group. Among
all of the patients, 20 % were 75 years old or older. K-PS
before treatment was not over 80 % in 16 cases. Supracla-
vicular LN metastasis was seen in 4 cases and abdominal
para-aortic LN metastasis in 4 cases, although these me-
tastases involved distant and not regional LNs.
Compliance with CRT
Twenty-one (24 %) patients completed four cycles, and
94 % received two or more cycles (Table 2). The pre-
scribed full dose and complete cycles of chemotherapy
Fig. 1 Nedaplatin and S-1 combined with radiotherapy regimen treatment schema
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were administered to 64 patients (72 %) according to the
pre-treatment planning. The relative dose intensity
(RDI) of chemotherapy was 0–24 % in one case, 25–
49 % in 2 cases, 50–74 % in 4 cases, 75–89 % in 10
cases, and 90–100 % in 72 cases. Sixty-two subjects
(70 %) received treatment as outpatients. S-1 of the sec-
ond cycle was changed into 5-FU injectable solution in
one patient, because the fatigue and languor due to S-1
were severe. This decision was based on our previous
experience of using NDP plus 5-FU in definitive CRT for
esophageal cancer. As a result, these symptoms im-
proved after changing to 5-FU.
Only one patient (1.1 %) could not complete the
planned RT and discontinued treatment at the time of
19.8Gy in 11 fractions (Table 2). This patient had under-
gone surgery for benign colon disease a few months earlier
and the colon wall was perforated, so CRT was suspended
at this time. Seventeen patients (19.1 %) received RT up to
60Gy in 30 fractions (Table 2).
CRT toxicity
The worst toxicities that occurred during the treatment
period were grade 3-4 toxicities of neutropenia, leukopenia,
anemia, and thrombocytopenia, which occurred in 58, 64,
27, and 27 % of patients, respectively. Grade 4 neutropenia,
leukopenia, thrombocytopenia, and anemia occurred in 17,
12, 7, and 10 % of patients, respectively. Five patients de-
veloped febrile neutropenia. Grade 3 non-hematological
toxicity included infection in 12 %, mucositis/esophagitis
in 3 %, kidney in 3 %, fatigue in 3 %, diarrhea in 1 %, and
liver function in 1 % of patients (Table 3). Late grade 3 ra-
diation pneumonitis that needed administration of steroids
and grade 3 esophageal stenosis were seen in two patients
and two patients, respectively (Table 2). Late grade 4 cere-
bral infarction occurred in one patient. Therapy-related
myelodysplastic syndrome developed in one patient. There
was only one treatment-related death, which was heart fail-
ure at 37 days after start of CRT. This patient had pre-
existing angina pectoris.









≧ 90 % 72 80.9
< 90 % 17 19.1
Location of tumor
Cervix 5 5.6
Upper thorax 15 16.9
Middle thorax 46 51.7
















Squamous cell carcinoma 86 96.6



















Grade 5 1 1.1
Grade 4 2 2.2
Grade 3 4 4.5
State at censoring
Alive without disease 49 55.1
Alive with disease 13 14.6
Dead of disease 13 14.6
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Efficacy
The median follow-up time of 65 living patients was
11.2 months (range: 1.3–47.2 months). Two patients re-
ceived salvage sub-total esophagectomy for loco-regional
recurrence after definitive CRT. At the end of follow-up,
31 patients (35 %) experienced disease recurrence or
local residual disease. The estimated 2- and 3-year over-
all survivals according to the Kaplan–Meier method
were 62.9 % (95 % CI; 47.8–78.0 %) and 54.4 % (95 % CI;
37.3–71.5 %), respectively, in definitive CRT and 59.7 %
(95 % CI; 20.9–98.5 %) and 39.8 % (95 % CI; 0–80.8 %),
respectively, in salvage CRT (Fig. 2). The estimated 3-
year overall survivals in definitive CRT were 73.8 %
(95 % CI; 46.8–100 %) in stage I, 47.8 % (95 % CI; 27.4–
68.2 %) in stage II-III, and 75.0 % (95 % CI; 32.5–100 %)
in stage IV. The estimated 2- and 3-year loco-regional
control rates for all 89 patients were 70.6 % (95 % CI;
57.5–83.7 %) and 57.9 % (95 % CI; 38.5–77.3 %), respect-
ively, and the estimated 2- and 3-year disease-free survival
rates for all 89 patients were 51.2 % (95 % CI; 37.5–
64.9 %) and 39.9 % (95 % CI; 22.1–57.7 %), respectively.
Discussion
A combination of radiation therapy (RT) with chemo-
therapy for esophageal cancer in randomized trials has
been used to try to improve local control and survival,
and cisplatin (CDDP) and 5-FU seem to be the key
drugs in these treatment protocols [17–19]. NDP is a
platinum derivative that was developed with the aim of
reducing renal toxicity while maintaining the effective-
ness of CDDP. In an in vivo study, a combination of
NDP and 5-FU has been shown to be as effective as a
combination of CDDP and 5-FU. In a clinical study,
combination chemotherapy using NDP and 5-FU has
been reported to be a safe and effective method for
treating advanced esophageal cancer. Based on these
facts, when the patient’s renal or cardiac function was
bad, we had given NDP in place of CDDP since 2000
(i.e. NDP plus 5-FU regimen which is different from
NDP plus S1 of this study), because NDP has less renal
toxicity than CDDP and because the vigorous hydration
needed to safely protect against cisplatin-related nephro-
toxicity might affect cardiac function. Radiation com-
bined with NDP and 5-FU was a safe and effective
method for treating esophageal cancer. In our previous
study [4], a combination of NDP plus 5-FU was compar-
able to that of CDDP plus 5-FU in survival, loco-regional
and distant control, clinical response, and both acute and
late toxicity, despite the NDP group had significantly more
stage IVB patients (more than 50 %) than did the CDDP
group. This chemotherapy regimen was NDP/5-FU and
not NDP/S1 as in the present cohort.
The current guidelines such as those of the European
Society for Medical Oncology (ESMO) [20] and National
Comprehensive Cancer Network (NCCN) (Version 3.
2015) regard carboplatin/paclitaxel as an alternative
non-fluoropyrimidine regimen. In many countries, this
treatment is considered a standard alternative treatment
for concurrent CRT as described in the CROSS (Chemo-
radiotherapy for Oesophageal Cancer Followed by
Surgery Study) trials [21]. Additionally, oral capecitabine
can be used as an alternative to 5-FU according to
NCCN guidelines. However, in Japan, carboplatin, pacli-
taxel, and oral capecitabine are currently not included
Table 3 Toxicity to chemoradiation by CTCAE v.4.0
All grades Grade 3 Grade 4
No. % No. % No. %
Neutropenia 82 92.1 37 41.6 15 16.9
Febrile neutropenia – 5 5.6 0
Leukopenia 83 93.3 46 51.7 11 12.4
Thrombocytopenia 78 87.6 18 20.2 6 6.7
Anemia 88 98.9 15 16.9 9 10.1
Nausea 25 28.1 0 0
Emesis 8 9.0 0 0
Diarrhea 18 20.2 1 1.1 0
Mucositis 64 71.9 3 3.4 0
Alopecia 0 0 0
Skin 30 33.7 0 0
Neuropathy 9 10.1 0 0
Fatigue 68 76.4 3 3.4 0
Liver 51 57.3 1 1.1 0
Cardiac toxicity 1 1.1 0 0
Pulmonary embolism 0 0 0
Kidney 25 28.1 3 3.4 0
Infection 44 49.4 11 12.4 0
CTCAE = common toxicity criteria
Fig. 2 Overall survival curves by the Kaplan–Meier method in
definitive and salvage CRT
Yamashita et al. Radiation Oncology  (2016) 11:4 Page 5 of 7
by insurance adaptation in CRT for esophageal cancer
with definitive intent. On the other hand, both S1 and
NDP are within insurance coverage for esophageal can-
cer. The costs of NDP plus S1 in Japan are at least com-
parable to other drug regimens such as capecitabine plus
CDDP or carboplatin plus paclitaxel. The carboplatin
plus taxane regimen may be also useful as an alternative
in terms of efficacy and toxicity in the definitive CRT, al-
though this regimen has been tested mainly in the neo-
adjuvant setting [21].
Tanaka et al. [22] performed a phase I dose-escalation
study on docetaxel, NDP, and S-1 chemotherapy without
RT for advanced esophageal carcinoma with T3-4 tumors
and/or M1 staging and esophageal carcinoma with cervical
lymph node metastasis. There are no other clinical studies
published on NDP treatment in combination with S-1.
Minsky et al. [23] reported the activity and toxicity of
definitive CRT with 5-FU and CDDP in 218 patients
with T1-4/N0-1 esophageal cancer. Their chemotherapy
consisted of 5-FU at a dose of 1,000 mg/m2/day on days
1–4, 29–32, 57–60, and 85–88 plus CDDP at a dose of
75 mg/m2 on days 1, 29, 57, and 85. In 109 patients with
standard dose of 50.4 Gy in 28 fractions, acute grade 3–
5 toxicity was seen in 77/109 patients (71 %) and late
grade 3–4 toxicity was seen in 37/99 patients (37 %)
[23]. In their study, the 2-year OS was 40 %, median sur-
vival time was 18.1 months, and loco-regional failure
plus residual was 52 % [23]. Ishikura et al. [24] assessed
the long-term toxicity after definitive CRT for 139 pa-
tients with esophageal squamous cell carcinoma. The
CRT consisted of two cycles of CDDP 40 mg/m2 on days
1 and 8, and continuous infusion of 5-FU 400 mg/m2/d
on days 1 to 5 and 8 to 12, repeated every 5 weeks with
concurrent radiotherapy of 60 Gy in 30 fractions. Of 78
patients with complete remission, two patients died as a
result of acute myocardial infarction and grade 3–4 late
toxicities occurred with pericarditis in 10.3 %, heart fail-
ure in 2.6 %, pleural effusion in 10.3 %, and radiation
pneumonitis in 3.8 % of the patients [24]. These rates
were almost equal to ours (Table 3), although these
comparisons might not be valid because their inclusion
criteria were different from ours.
The radiation doses to the fresh cases were different
from those administered to recurrent tumors in our in-
stitution because we wanted to determine promptly
whether there are residual tumors and salvage surgery
for them should be adapted after definitive CRT, and we
stopped it in the 50–50.4 Gy dose range. The limitations
of this report were that this is a retrospective review and
that the treatments were not relatively homogeneous in
terms of including older patients and patients in both
definitive and salvage settings.
Most importantly, NDP plus S-1 can be administered
on an outpatient basis, whereas CDDP plus 5-FU, which
was used as the standard drug combination in CRT, re-
quires hospitalization of at least 4-5 days per cycle dur-
ing 5-FU administration. In this retrospective research,
30 % of the patients were treated as inpatients, at least
transiently. Twelve of these patients (13 %) were hospi-
talized up to 2 weeks and 10 patients (11 %) were hospi-
talized throughout RT. The majority of the admitted
patients were admitted because their homes were too far
away from the hospital, so it was difficult to commute,
or because of severe symptoms of esophageal stenosis by
the primary tumor.
Conclusion
NDP and S-1 in combination with radiotherapy is a feas-
ible treatment, and toxicity is tolerable. This treatment
method has the potential to shorten hospitalization
without impairing the efficacy of CRT.
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